Management of obesity in children differs from that of adults

Hilary Hoey1

  • 1Department of Paediatrics,Trinity College Dublin,Ireland.

Insights

Childhood obesity is a growing public health crisis. Early intervention and prevention strategies are crucial, as obese children often become obese adults facing serious health issues.

Area of Science:

  • Pediatrics
  • Public Health
  • Nutrition Science

Background:

  • Childhood obesity is a prevalent and escalating global health concern.
  • Obese children face increased risks of developing chronic diseases like diabetes and cardiovascular disease (CVD), alongside psychological and social challenges.
  • Overweight and obesity in childhood often persist into adulthood, making early intervention critical.

Purpose of the Study:

  • To raise awareness regarding the prevalence and severe complications of childhood obesity.
  • To emphasize the urgent need for effective prevention and management strategies.
  • To highlight children as a priority population for obesity intervention.

Main Methods:

  • Review of etiological factors including nutrition, physical activity, infant weight gain, and genetic/environmental influences.
  • Emphasis on family education and empowerment regarding diet and exercise.
  • Discussion of the role of environmental and social factors in shaping eating and activity behaviors.

Main Results:

  • Childhood obesity is largely preventable through targeted interventions.
  • Effective prevention requires addressing environmental and social factors that promote unhealthy eating and inhibit physical activity.
  • Governmental support for health promotion programs is vital for population-wide impact.

Conclusions:

  • Preventing and managing childhood obesity requires a multi-faceted approach involving families, healthcare providers, and government policy.
  • Early and consistent intervention, including regular medical check-ups and growth assessments, is essential.
  • Prioritizing childhood obesity prevention is critical for long-term public health outcomes.

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
437
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
364
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
954
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324